Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Balance Sheet: Liabilities and Stockholders’ Equity 

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Abbott Laboratories, consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings 213 201
Trade accounts payable 4,295 4,607 4,408 3,946 3,252
Salaries, wages and commissions 1,597 1,556 1,625 1,416 1,237
Accrued rebates payable to government agencies 650 638 364 316 212
Accrued other rebates 1,091 1,087 1,082 805 655
All other 3,681 4,120 3,735 4,044 3,168
Other accrued liabilities 5,422 5,845 5,181 5,165 4,035
Dividends payable 955 887 831 798 635
Income taxes payable 492 343 306 362 226
Current portion of long-term debt 1,080 2,251 754 7 1,277
Current liabilities 13,841 15,489 13,105 11,907 10,863
Long-term debt, excluding current portion 13,599 14,522 17,296 18,527 16,661
Defined benefit pension plans and post-employment medical and dental plans for significant plans 1,964 1,784 2,738 3,119 2,817
Deferred income taxes 568 991 1,392 1,406 1,546
Operating lease liability, non-current 949 943 956 902 755
All other 3,466 3,804 3,685 3,684 3,944
Post-employment obligations and other long-term liabilities 6,947 7,522 8,771 9,111 9,062
Long-term liabilities 20,546 22,044 26,067 27,638 25,723
Total liabilities 34,387 37,533 39,172 39,545 36,586
Preferred shares, one dollar par value, none issued
Common shares, without par value 24,869 24,709 24,470 24,145 23,853
Common shares held in treasury, at cost (15,981) (15,229) (11,822) (10,042) (10,147)
Earnings employed in the business 37,554 35,257 31,528 27,627 25,847
Accumulated other comprehensive loss (7,839) (8,051) (8,374) (8,946) (8,465)
Total Abbott shareholders’ investment 38,603 36,686 35,802 32,784 31,088
Noncontrolling interests in subsidiaries 224 219 222 219 213
Total shareholders’ investment 38,827 36,905 36,024 33,003 31,301
Total liabilities and shareholders’ investment 73,214 74,438 75,196 72,548 67,887

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Abbott Laboratories current liabilities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Abbott Laboratories long-term liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Abbott Laboratories total liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total Abbott shareholders’ investment Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Abbott Laboratories total Abbott shareholders’ investment increased from 2021 to 2022 and from 2022 to 2023.